U.S. approves breakthrough pancreatic cancer drug, heralding a new era for an intractable disease

• Food and Drug Administration just approved a new breakthrough drug for pancreatic cancer that significantly extends the lives of people with the disease—considered one of the most intractable and difficult to treat forms of cancer.
• The medication is called daraxonrasib and is manufactured by Revolution Medicines; it will be sold as Rasonque and takes the form of a two-pills-a-day regimen.